Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Merck Raises Vioxx, Arcoxia Guidance To $2.8 Bil.-$3 Bil. For 2004

This article was originally published in The Pink Sheet Daily

Executive Summary

The revised guidance is primarily related to the performance of Merck's coxib franchise in overseas markets. A potential fourth quarter U.S. launch of Arcoxia is not included in the guidance.

You may also be interested in...



Merck's Vioxx Gains First-Line Juvenile Rheumatoid Arthritis Indication

FDA approval marks first pediatric indication for COX-2 inhibitor class. Pfizer's competing COX-2s Celebrex and Bextra are not being developed for JRA; the Vioxx JRA approval is based on a single non-inferiority trial.

Entire COX-2 Class Is TARGET Of Critical Lancet Editorial

The TARGET study's mixed results on Novartis' Prexige prompted an editorial critique of the entire COX-2 inhibitor class of drugs.

Merck's Vioxx Gains First-Line Juvenile Rheumatoid Arthritis Indication

FDA approval marks first pediatric indication for COX-2 inhibitor class. Pfizer's competing COX-2s Celebrex and Bextra are not being developed for JRA; the Vioxx JRA approval is based on a single non-inferiority trial.

Topics

UsernamePublicRestriction

Register

LL1125120

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel